Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04346914
Other study ID # NTL-LEES-2019-03
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 8, 2020
Est. completion date October 30, 2022

Study information

Verified date May 2022
Source Lee's Pharmaceutical Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the safety and efficacy of recombinant anti-PD-L1 monoclonal antibody injection (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small cell lung cancer.


Description:

To evaluate the safety and preliminary efficacy of recombinant anti-PD-L1(Programmed cell death ligand 1)monoclonal antibody injection (ZKAB001) combined with carboplatin and etoposide in the treatment of extensive-stage small cell lung cancer. The study will last until the number of patients who permanently stop taking drugs due to toxicity in the first two cycles is less than 1/3 of the total number of patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date October 30, 2022
Est. primary completion date October 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - both men and women, age = 18 years old and = 75 years old. - histologically confirmed SCLC - extensive stage SCLC (ES-SCLC) according to (VALG) staging of American Veterans Lung Cancer Association. - have not received first-line systemic therapy for ES-SCLC in the past. - surgery and adjuvant therapy for cure, such as radiotherapy and chemotherapy, were performed in the past, and there was no treatment interval of at least 6 months from the last chemotherapy, radiotherapy or radiotherapy or chemotherapy to the diagnosis of ES-SCLC. - PS 0 or 1. - estimated survival time > 12 weeks. - CT or MRI scan with at least one measurable lesion less than 28 days before the first dose of the study drug (RECIST v1.1). - male subjects and women of childbearing age must have contraception within 6 months from the beginning of the first drug study to the last study drug. - before the first dose of the drug, the laboratory test values met the following conditions: (1) Blood routine test: WBC = 3.0x10^9 / L, ANC = 1.5x10^9 /L, PLT = 100x10^9 /L, hGB = 90g / L; (2) liver function: AST = 2.5 ULN, ALT = 2.5 ULN; ALT and AST < 5 ULN for liver metastases; TBIL = 1.5 ULN; ALB = 30 g L; (3) Renal function: serum creatinine = 1.5 ULN or creatinine clearance rate (Ccr) = 40 mL/min (Cockcroft/Gault formula); (4) Coagulation function: INR = 1.5, APTT = 1.5 ULN; (5) ALP = 2.5 ULN, ALP = 5 ULN. for bone metastasis subjects, - tumor tissue samples that can meet the detection of PD-L1 expression can be provided during the screening period and within 4 weeks after selection. - voluntarily sign informed consent form (ICF) Exclusion Criteria: - before entering the group, the patients received any T cell co-stimulatory or immune checkpoint inhibitors, including, but not limited to, cytotoxic T lymphocyte associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1/2 inhibitors or other drugs targeting T cells; previously received anti-vascular endothelial growth factor (VEGF) or vascular endothelial growth factor receptor (VEGFR) therapy. - active brain metastasis or meningeal metastasis. - Patients with brain metastasis after treatment need to meet the following conditions: asymptomatic; no imaging evidence of progress = 4 weeks after treatment; completion of treatment within 14 days before the first dose of the study drug; and no need to receive systemic corticosteroids (> 10mg/ prednisone or equivalent) less than 14 days before the first dose of the study drug. - radiotherapy for the chest and whole brain was completed less than 4 weeks before the first dose of the study drug (palliative radiotherapy for bone lesions is allowed ). - the third space effusion with clinical symptoms, such as pericardial effusion, pleural effusion and peritoneal effusion which cannot be controlled by pumping or other treatment. - active, known or suspected autoimmune diseases. Patients with vitiligo, type I diabetes, residual hypothyroidism caused by autoimmune thyroiditis that only require hormone replacement therapy, or are not expected to recur in the absence of external stimulation can be included in the group. - corticosteroids (> 10 mg/ prednisone or equivalent dose) or other immunosuppressants were used within 14 days before the first study. Inhalation or topical use of steroids and adrenal replacement steroids are allowed in the absence of active autoimmune disease; for patients receiving short-term, systemic immunosuppressive therapy, for example, glucocorticoids for nausea, vomiting, or allergic reaction management or preventive use can be admitted after consultation with the sponsor. Allow the use of salt corticosteroids in the treatment of postural hypotension and the use of low-dose glucocorticoid supplements in the treatment of adrenocortical insufficiency; - subjects who had been vaccinated or planned to receive live vaccines within 4 weeks before the first study. - Interstitial pneumonia (ILD) disease, drug-induced pneumonia, radiation pneumonia requiring steroid treatment or active pneumonia with clinical symptoms. - active pulmonary tuberculosis or screening subjects with a history of active pulmonary tuberculosis infection within 1 year before treatment, whether treated or not. - except for alopecia and fatigue, other toxicities caused by previous antineoplastic therapy need to be restored to CTCAE 5.0 = 1 before the first dose. Some other toxicities caused by previous antineoplastic therapy are not expected to be resolved and have long-term persistent sequelae, such as neurotoxicity caused by platinum-based therapy, which are allowed to be included in the group. - uncontrolled hypertension (systolic blood pressure = 140mmHg and / or diastolic blood pressure = 90 mmHg), history of hypertensive crisis or hypertensive encephalopathy. - there are uncontrolled clinical symptoms or diseases of the heart, such as: (1)heart failure defined by New York Heart Association (NYHA)in grade 2 or above (2) unstable angina pectoris (3) myocardial infarction within 6 months (4) clinically significant supraventricular or ventricular arrhythmias need to be treated. - uncontrolled active infections (e.g. need intravenous antibiotics, antifungal or antiviral therapy). - HIV infection, HBsAg positive and peripheral blood HBV-DNA titer = 0.5 × 10^3 copies / mL or HCV positive (HCV RNA or HCV Ab test indicated acute or chronic infection). - pregnant or lactating women. - known allergies to study drugs or excipients, and known severe allergic reactions to any monoclonal antibody; allergic history of carboplatin or etoposide. - other malignant tumors occurred less than 5 years before the first dose, except for fully treatable cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, ductal carcinoma in situ after radical resection, and breast cancer without recurrence and metastasis after radical resection. - known cases of mental illness, alcohol abuse, inability to quit smoking, drug use or substance abuse. - have been treated with any other experimental drugs or participated in another interventional clinical study within 4 weeks before signing ICF

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
ZKAB001 ,5 mg/kg, d1,q3w; carboplatin,5 AUC,d1,q3w; etoposide,100mg/m2,d1~3,q3w

Locations

Country Name City State
China Shanghai Chest Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Lee's Pharmaceutical Limited

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary DLT The number of patients who permanently stop taking drugs due to toxicity is less than 1/3 of the total number of patients. 28 days after first dose
Secondary objective response rate Percentage of patients in partial and complete response 12 months
Secondary progression free survival time between first dose of study drug to disease progression 12 months
Secondary The positive rate of PD-L1 expression in tumor tissue The positive rate of PD-L1 expression in tumor tissue. 12 months
Secondary The positive rate of anti-drug antibody (ADA); The positive rate of anti-drug antibody (ADA); 12 months
Secondary overall survival time between first dose of study drug to death caused by any reason 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05903092 - MOnaliZumab in Combination With durvAlumab (MEDI4736) Plus Platinum-based chemotheRapy for First-line Treatment of Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT01935336 - Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Phase 2
Completed NCT00544596 - R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT04063163 - A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy (Carboplatin- Etoposide) in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Phase 3
Terminated NCT01217411 - RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Phase 1
Completed NCT00773955 - R-(-)-Gossypol Acetic Acid in Treating Patients With Recurrent Extensive-Stage Small Cell Lung Cancer Phase 2
Completed NCT00528645 - AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05468489 - To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC Phase 2
Active, not recruiting NCT00828139 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05896059 - A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC Phase 2
Recruiting NCT06323265 - A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung Cancer
Withdrawn NCT01325753 - Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body N/A
Completed NCT00019006 - Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer Phase 1
Not yet recruiting NCT04933175 - Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer Phase 2
Recruiting NCT02972320 - Extensive Stage Sclc Patients Who Were Benefit From First-line Treatment Accept Temozolomide Maintain Therapeutic Phase 2
Completed NCT01331525 - The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer Phase 2
Completed NCT01155258 - Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors Phase 1
Terminated NCT00088933 - Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer Phase 1
Completed NCT00020202 - FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer Phase 2
Completed NCT02194049 - Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer Phase 1